From Medscape Neurology

Coverage from the

Consortium of Multiple Sclerosis Centers (CMSC) 2022 Annual Meeting

June 01 - 04, 2022; National Harbor, Maryland

June 01 - 04, 2022 National Harbor, Maryland
  • CMSC 2022 Novel Drug Safe, Effective in Relapsing MS: 2-Year Data The investigational evobrutinib, an Bruton's tyrosine kinase inhibitor, showed favorable safety and efficacy in the longest trial to date of a drug in this class in patients with multiple sclerosis.
  • CMSC 2022 Non-White MS Patients Rarely Included in Trials Over 25 years of clinical research, phase 3 trials of approved disease-modifying therapies for multiple sclerosis were overwhelmingly made up of White participants, new research shows.

Conference News

Popular News from CMSC 2021

Medscape Neurology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Previous Coverage